Drug Approval | March 21, 2022
Glenmark receives ANDA approval for Lacosamide tablets
The company plans to launch the product immediately
The company plans to launch the product immediately
The drug is indicated for use in combination with other drugs
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The facility will produce 150 million vaccine doses per year
The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Successful proposals will secure fully funded postdoctoral research positions
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Subscribe To Our Newsletter & Stay Updated
